Why Abiomed (ABMD) Could Beat Earnings Estimates AgainHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Why Abiomed (ABMD) Could Beat Earnings Estimates AgainZacks Equity ResearchZacksJanuary 3, 2020ReblogShareTweetShareIf you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Abiomed (ABMD). This company, which is in the Zacks Medical - Instruments industry, shows potential for another earnings beat.This maker of heart devices has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 5.88%.For the last reported quarter, Abiomed came out with earnings of $1.03 per share versus the Zacks Consensus Estimate of $0.93 per share, representing a surprise of 10.75%. For the previous quarter, the company was expected to post earnings of $0.99 per share and it actually produced earnings of $1 per share, delivering a surprise of 1.01%.Price and EPS SurpriseThanks in part to this history, there has been a favorable change in earnings estimates for Abiomed lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.Abiomed currently has an Earnings ESP of +2.75%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner.With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss.Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ABIOMED, Inc. (ABMD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment ResearchReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextDell Technologies (DELL) Matches Q4 Earnings EstimatesZacksPRA Group (PRAA) Q4 Earnings and Revenues Top EstimatesZacksRedwood Trust (RWT) Q4 Earnings and Revenues Top EstimatesZacksFS KKR Capital (FSK) Tops Q4 Earnings EstimatesZacksPlaya Hotels & Resorts (PLYA) Reports Q4 Loss, Tops Revenue EstimatesZacksRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoHere are 5 reasons the stock market is having its worst decline since 2008, and only one of them is the coronavirusMarketWatchMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video